Xilio Therapeutics (NASDAQ:XLO) Shares Cross Below Two Hundred Day Moving Average – Here’s What Happened

Xilio Therapeutics, Inc. (NASDAQ:XLO)’s stock price crossed below its two hundred day moving average during trading on Wednesday. The stock has a two hundred day moving average of $8.50 and traded as low as $8.40. Xilio Therapeutics shares last traded at $8.47, with a volume of 3,529 shares trading hands.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on the stock. Zacks Research raised shares of Xilio Therapeutics to a “hold” rating in a report on Thursday, October 22nd. Raymond James Financial began coverage on Xilio Therapeutics in a research note on Wednesday, October 21st. They issued an “outperform” rating and a $16.00 price target for the company. Finally, Weiss Ratings upgraded Xilio Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, November 4th. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Xilio Therapeutics has a consensus rating of “Hold” and an average price target of $16.00.

Xilio Therapeutics Trading Down 0.7%

The company has a market cap of $55.73 million, a price-to-earnings ratio of -21.17 and a beta of -0.13. The business has a fifty day moving average of $8.74 and a two-hundred day moving average of $8.50.

Xilio Therapeutics (NASDAQ:XLO) last released its earnings results on Tuesday, November 10th. The company reported ($0.30) EPS for the quarter, topping analysts’ consensus estimates of ($0.94) by $0.64. Xilio Therapeutics had a negative net margin of 20.89% and a negative return on equity of 62.61%. The business had revenue of $9.98 million during the quarter, compared to analysts’ expectations of $4.92 million. On average, research analysts forecast that Xilio Therapeutics, Inc. will post -3.17 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the company. BlackRock Inc. acquired a new stake in Xilio Therapeutics in the 2nd quarter valued at about $84,000. State Street Corp purchased a new stake in shares of Xilio Therapeutics during the second quarter worth approximately $128,000. Finally, Stonepine Capital Management LLC lifted its position in Xilio Therapeutics by 252.2% in the second quarter. Stonepine Capital Management LLC now owns 225,994 shares of the company’s stock valued at $2,165,023 after purchasing an additional 161,832 shares during the period. 54.29% of the stock is currently owned by institutional investors and hedge funds.

About Xilio Therapeutics

Xilio Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing tumor-activated immunotherapies for cancer. The company’s technology is designed to keep powerful immune-modulating medicines inactive in healthy tissue and activate them preferentially within the tumor microenvironment, with the goal of improving antitumor activity while reducing systemic side effects. Xilio’s research and development programs have included engineered cytokines and immune checkpoint therapies, including tumor-activated versions of interleukin-2, interleukin-12 and CTLA-4-directed treatments.